SINGAPORE, May 12, 2024
/PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage
biotechnology company developing novel immunotherapies for
infectious diseases and their associated cancers, announced first
preclinical data of its novel human papillomavirus (HPV)-specific T
cell receptor-engineered T (TCR T) cell therapy armored with an
TGFβRII-41BB immunoswitch – SCG142 – in an oral presentation
at the American Society of Gene & Cell Therapy (ASGCT) Annual
Meeting in Baltimore,
Maryland.
In preclinical studies, SCG142 demonstrated superior
CD8+ and CD4+ TCR T cell proliferation
and tumor inhibition both in-vitro and in-vivo
compared to conventional TCR T without immunoswitch, including
tumor rechallenge models. Importantly, SCG142 functionality is CD8
co-receptor independent, transferring desired effector functions
also to CD4+ T cells and promoting longer persistence and improved
proliferation of T cells. In addition, SCG142 exhibited high
functional avidity and can recognize both genotypes HPV-16 and
HPV-52, with a favorable safety profile with no alloreactivity or
off-target toxicity in relevant toxicology models.
"SCG142 is a novel and differentiated HPV-specific TCR T cell
therapy with preclinical efficacy in various tumor types with
expression of HPV-16- and HPV-52 genotypes. We're excited to
demonstrate that armoring the TCR-T cells with the chimeric switch
receptor didn´t change the favorable safety profile but helped to
overcome the immune inhibitory signal of TGF-β, which can be
crucial for effective treatment of solid tumors", said Dr.
Susanne Wilde, Head of Preclinical
Research of SCG Cell Therapy. "These promising results
underscore the potential of SCG142 to provide new solutions for
patients in a variety of HPV-16- and HPV-52 expressing cancers.
Based on these encouraging data, we are eagerly advancing SCG142
towards clinical trials", she added.
About SCG142
SCG142, an autologous HPV-specific TCR T
cell therapy holding the promise as the best-in-class product.
Utilizing SCG's proprietary GianTCRTM technology, high
affinity and high avidity natural TCRs can be isolated to target
against intracellular antigens presented through major
histocompatibility complex (MHC) in solid tumors. Study results
showed that SCG142, a fully natural HPV specific TCR armoured with
chimeric switch receptor, has the potential to specially target
HPV-16 and HPV-52-positive tumor cells in various HPV-related tumor
types, generating CD8 co-receptor independent T cell functionality
and sustained anti-tur activity.
About Human Papillomavirus and Cancers
Human
papillomavirus (HPV) infection is the most common sexually
transmitted infection. Nearly all sexually active people are
infected with HPV and around half of these infections occur with a
high-risk HPV type, which can lead to cancer
development.1 As such, HPV infection accounts for
more than 90% of anal and cervical cancers, about 70% of vaginal
and vulvar cancers, and 60% of penile and oropharyngeal cancers,
and it causes an estimated 630,000 cancers worldwide each
year2x.
About SCG Cell Therapy
SCG is a leading biotechnology
company focusing on the development of novel immunotherapies in
infections and its associated cancers. The company targets the most
common cancer-causing infections: helicobacter pylori, HPV, HBV and
EBV, and develops a broad and unique pipeline of TCR-based cellular
immunotherapy products against infection- associated cancers. With
the proprietary GianTCRTM TCR screening platform, in
house viral vector production and AutoCellTM, a fully
closed and automatic cell therapy manufacturing system, the company
covers the entire value chain from new target research and
discovery, manufacturing, and clinical development. For more
information about SCG, please visit us at www.scgcell.com.
[1] HPV and cancer. National Cancer Institute. (2023,
October 18)
[2] Basic information about HPV and cancer. Centers
for Disease Control and Prevent (2023, September 12)
View original
content:https://www.prnewswire.com/news-releases/scg-cell-therapy-presented-new-preclinical-data-in-an-oral-presentation-at-asgct-2024-annual-meeting-highlighting-superior-tumor-inhibition-of-its-immunoswitch-armored-hpv-tcr-t-cell-therapy-scg142-against-a-broad-range-of-hpv-a-302143142.html
SOURCE SCG Cell Therapy Pte Ltd